



LEERINK SWANN

**Novel Cancer Therapeutics Roundtable Conference
Wednesday, May 20, 2009**

Howard Hochster MD

Dr Hochster is Professor of Medicine and Clinical Pharmacology at New York University (NYU) School of Medicine in the Division of Medical Oncology at the NYU Cancer Institute. In addition, Dr Hochster currently serves as the Director of the NYU Cancer Institute's Gastrointestinal Program and the Developmental New Agents and Targets Program and is an attending physician at Tisch Hospital at the NYU Langone Medical Center and Bellevue Hospital Center. Dr Hochster is an international leader in research and drug development for gastrointestinal (GI) cancer treatment. His research interests include novel therapies for GI cancers such as topoisomerase-1. Included among his numerous publications in the area of early clinical trials are manuscripts focusing on the scheduling and pharmacodynamics of topo-1 inhibitors, oxaliplatin development, newer fluoropyrimidines, and anti-metabolite pharmacodynamics and targeted therapy. He currently serves as principal investigator for the Eastern Cooperative Oncology Group (ECOG) at NYU and is a member of the GI Steering Committee. In addition, he has served as Chair of the NYU Cancer Institute's Clinical Executive Management Committee, Director of its Developmental Therapeutics Unit, and Medical Director of the NYU Cancer Institute's Clinical Trials Office. Dr Hochster is also the national Director of Early Drug Development for Aptium Oncology Research Network and on the steering committee of the Aptium GI Cancer Consortium (AGICC).

William Matsui MD

Dr Matsui joined the faculty in the Department of Oncology at the Johns Hopkins University School of Medicine in 2002 and is currently an Associate Professor. He received his medical degree from the University of California at San Francisco in 1995 and completed his residency training in Internal Medicine at the University of Washington in Seattle. Dr Matsui fulfilled his clinical training in Medical Oncology as a Clinical Fellow in medical oncology at Johns Hopkins. The primary focus of Dr. Matsui's laboratory is studying cancer stem cells. His clinical interests include the development of novel anti-cancer strategies and bone marrow transplantation.

Ruben Niesvizky MD

Dr Niesvizky is Associate Professor of Clinical Medicine at Weill Medical College of Cornell University and at New York Presbyterian Hospital/Weill Cornell Medical Center in Manhattan. He also serves as Director of the Multiple Myeloma Service at the Center of Excellence for Lymphoma and Myeloma at New York Presbyterian Hospital-Cornell Medical Center. After receiving a medical degree from National University of Mexico, Dr Niesvizky did a research fellowship in cell biology-granulomonopoiesis and an internal medicine residency at the National Institute of Nutrition in Mexico. He then completed fellowships in New York: one (hematology) at Mount Sinai Medical Center, one (hematology/medical oncology) at Memorial Sloan-Kettering Cancer Center, and one (medicine) at Cornell University Medical Center. He has written more than 50 articles, editorials, chapters, and abstracts published in journals such as New England Journal of Medicine, Blood and Leukemia & Lymphoma, most recently on topics such as the treatment of myeloma and Waldenstrom's macroglobulinemia. He is the recipient of various grants and awards from the National Cancer Institute, including a K23 award and two translational research grants. He recently received the 2007 Investigator Award of the Michael Wolk Heart Foundation. A frequent lecturer, Dr Niesvizky regularly presents at annual meetings of the American Society of Hematology and the American Society of Clinical Oncology, of which he is also a member. He is an active participant in clinical trials of promising new drugs and medical procedures for the treatment of myeloma, lymphoma, and related hematologic disorders.

Ariela Noy MD

Dr Noy is a member of the Lymphoma and Hematology Division at the Memorial Sloan-Kettering Cancer in New York City. She has expertise in the treatment of a wide variety of hematological malignancies with particular emphasis on Hodgkin's disease, non-Hodgkin's lymphoma and AIDS related malignancies. She is a member of The AIDS Malignancy Consortium, serving on its Executive Committee as Chair of the Lymphoma Working Group and a participant in the Kaposi's sarcoma Working Group. Dr. Noy's other research interests include advancing therapies for lymphoma, the evaluation of minimal residual disease in patients with lymphoid malignancies, preservation of infertility during treatment, and the role of PET scanning in lymphoma. She also serves as a Reviewer for national and international journals.

Daniel Petrylak MD

Dr Petrylak is an Associate Professor of Medicine at Columbia University School of Medicine in the Hematology and Oncology Division. Since 1995, Dr. Petrylak has been the Program Director of the Genitourinary Oncology Section in the Division of Hematology/Oncology at Columbia University Medical Center. Dr. Petrylak is involved in clinical trials research on a local, national, and international level. He is the Head of the advanced bladder subcommittee in the Southwest Oncology Group Genitourinary Committee. Dr. Petrylak served as PI or Co-PI on 7 Southwest Oncology Group Protocols. Most notably, he served as the PI for a randomized trial comparing docetaxel and estramustine to mitoxantrone and prednisone in men with hormone refractory prostate cancer. This trial was one of two studies that demonstrated a survival benefit for docetaxel-based therapy in men with advanced prostate cancer. This trial supported the approval of docetaxel for hormone refractory prostate cancer by the FDA. He also helped to design and served as principal investigator for, the SPARC trial, an international registration trial evaluating the activity of satraplatin as a second line therapy for hormone refractory prostate cancer. He has served on the program committee for the annual meetings of the American Urological Association as well as for the American Society of Clinical Oncology. He also has served as a committee member for the Devices and Immunologicals section of the Food and Drug Administration (FDA).